Synairgen Share Discussion Threads

[wetdream] 10/4/2020 17:07

ADVFN member since 8/4/20.
Uh,oh....

[amaretto1] 10/4/2020 13:11

Some top boys + Girls in the staff room .. helps !

[amaretto1] 10/4/2020 13:11

True... they have 11 to go at, so not a one trick pony :-)

[toffeeman] 10/4/2020 12:48

Everything has blockbuster potential except most stocks:)

[amaretto1] 10/4/2020 11:52

I'm hearing good things about the company .. up coming news, Was just trying to get thoughts from others on here.Words were "blockbuster potencial"

[toffeeman] 10/4/2020 11:47

I am in SNG, C4XD, AVCT. GDR, FARN

I think they all have potential (well I would wouldn't I!)

My positions in C4XD, GDR FARN and AVCT are very small (via Guinness AIM EIS - so tax benefit) - I am into SNG in a much bigger way.

I like the portfolio approach but I am really not sure about C4XD, but I did take out a £20 a point SB the other week which is under water. I certainly wouldn't bet the farm.

[amaretto1] 10/4/2020 11:42

What u think of CX4D ? Potencial ?

[amaretto1] 10/4/2020 11:38

Any links to here ?

[jrlomax] 10/4/2020 11:37

Are there any side effects with this treatment?

[2nell] 10/4/2020 11:27

9 April 2020
Article on the BBC

There have been one-and-a-half million cases of Covid-19 around the world, and 55,000 in the UK, with over 6,000 people dying. It's hard to think of the peace when you're in the middle of the war. However, we do need an exit strategy.

A vaccine will be found, but this is at least a year away, and if we're going to save precious lives, we desperately need effective treatments today. To do that, we need to harness the best medical research in the UK.

Now is the time to combine all our bright research lights and shine them on to Covid-19.

That's why we at Bradford Royal Infirmary are taking part in the Recovery trial. It stands for Randomised Evaluation of Covid-19 Therapy, and is recruiting anyone over the age of 18 who is admitted into hospital with coronavirus.

All patients will be randomly allocated to one of five arms, and be given either a placebo or one of four experimental treatments. More than 130 hospitals are involved, including St Thomas' in London, where Prime Minister Boris Johnson has been being treated. As of today, towards the end of the second week, 2,000 patients have been recruited, of whom 30 are in Bradford.

Image copyrightJOHN WRIGHT
Prof John Wright, a medical doctor and epidemiologist, is head of the Bradford Institute for Health Research. He has looked after patients in epidemics all over the world, including cholera, HIV and ebola outbreaks in sub-Saharan Africa. Over the next few weeks he will be reporting for the BBC on how his hospital, the Bradford Royal Infirmary, is coping with Covid-19.

Read his previous diary entries:

Our hospitals weren't made to use this much oxygen
Why are people stealing hospital supplies?
Making life-and-death decisions
This is one of the advantages of having a National Health Service. We've never been so co-ordinated, having one big trial, and trying to recruit everybody in the country.

It's the biggest and most urgent research race in living memory, and we are running for our lives.

On Tuesday I accompanied Dr Dinesh Saralaya on the morning ward round in Ward 31, which is where the first of our Covid-19 patients were admitted, and which remains the centre of our fightback. Since then our infectious "red zone" has expanded - the red tide constantly gets higher and higher, seeping through the hospital. We've had more than 200 cases and 30 deaths.

Dinesh introduced me to a patient in his 40s who described the symptoms he'd started having about 12 days earlier.

"The first three days I'd say it was shivers, and temperature and then I lost the appetite and my taste. And then my cough got really bad. And at night time it was just like an attack of cough - and then it just doesn't stop," he said.

He'd also been having nose bleeds.

After three days in hospital he was already feeling a lot better.

Listen to John Wright
John Wright is recording from the hospital wards for BBC Radio 4's The NHS Front Line
You can hear the next episode at 11:00 on Tuesday 14 April, catch up with the previous episodes online, or download the podcast
At that point it was time to turn him on to his stomach - "tummy time", as the nurses call it - which often makes it easier for patients to breathe.

It was explained to him when he consented to take part in the trial that he might be given a placebo. The other four possibilities are:

Hydroxychloroquine, the antimalarial drug that President Trump said he had a good feeling about - which then led to a spate of overdoses and acute shortages
Kaletra, a combination of antiretroviral drugs used in treating HIV
Dexamethasone, a steroid, which is an old favourite in medicine when we don't quite know what's going on
Interferon, a cytokine, which may help fight the infection

[141jaffa] 10/4/2020 11:25

.....and LRTI's !!

[141jaffa] 10/4/2020 11:22

Recovery trial; Also wonder if SNG sits slightly outside "recovery" treatment maybe and more into "early intervention /prevention". Obviously a potentially huge market and benefit to many people. I guess stock piles depend on cost and shelf life etc.

Even if this drug shows some benefit,but not THE "cure", it may be beneficial in adjunct /combination therapy with other drugs(v) viral respiratory infections, CV19 or otherwise. I think a lot of viral URTI's can start as viral and then secondary bacterial infections can set in.

[pdt] 10/4/2020 10:47

This article shows how badly COPD patients are affected by this;

[d1nga] 10/4/2020 10:35

Toffeeman, the cost benefit is the lack of care these people no longer require on an ongoing basis, once you have damaged the lungs each exacerbation causes more scarring and the patients end up in and out of hospital on a very regular basis, I know this by experiencing it, you see the same patients in the same respiratory ward on a regular basis, the cost to the NHS must be astronomical, if this drug can reduce the damage to the lungs at the start it really could be priced highly but still save lots of cash to the NHS but more importantly give people a chance to live a normal life.

[nobbygnome] 10/4/2020 10:33

It's binary wrt the Covid 19 trial but not from the bigger picture. The COPD trial which is in more patients could produce a positive result even if the Covid 19 trial is negative because of the small size.

Talking of the COPD trial, they were looking to change the protocol there to make the last 11 patients Covid 19 infected COPD patients. That would be another announcement to give the share price a boost!

[toffeeman] 10/4/2020 10:27

I don't think it's completely binary - it's about (unfortunately) cost-benefit.

Being realistic I think the BEST we can expect is that it works for SOME indications but only for SOME people and the detail will take a long long time to work out.

Mind you I don't see the share price dropping to 6p and so (answering my own question above) unless I can fine a better investment going forward, I should leave well alone - except that SNG now comprises 25% of my stocks and shares ISA - too much??

Happy Easter Nobby and thanks for your efforts here.